Nine-valent human papillomavirus (HPV) vaccine could prevent 85% of cervical cancers
the ONA take:
According to new research published in the journal Caner Epidemiology, Biomarkers & Prevention, a new nine-valent human papillomavirus (HPV) vaccine after researchers found nine HPV subtypes cause the majority of cervical cancers. Researchers say that 85% or more of precancerous cervical lesions were caused by HPV subtypes 6, 11, 16, 18, 31, 33, 42, 52, and 58. For the study, the researchers analyzed data from three clinical trials studying a quadrivalent HPV vaccine that protects against subtypes 6, 11, 16, and 18. They identified 2,507 women aged 15 to 45 diagnosed with cervical intraepithelial neoplasia 1(CIN1), CIN2, CIN3, or adenocarcinoma in-situ (AIS).
With the nine HPV subtypes included in the investigational HPV vaccine, which is being developed by Merck and under review with the U.S. Food and Drug Administration, in mind, the researchers estimated the number of precancerous lesions triggered by those nine HPV subtypes in the 2,507 women. After adjustments, they found that seven of the nine HPV subtypes included in the vaccine were present in approximately 55% of CIN1, 78% of CIN2, 91% of CIN3, and 100% of AIS lesions. Some women were infected with multiple HPV subtypes.
Researchers found nine HPV subtypes cause the majority of cervical cancers
Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
"We wanted to study how many cervical precancers could potentially be prevented by an investigational nine-valent HPV vaccine that provides protection against the HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58," said Elmar A. Joura, MD, an associate professor of gynecology at the Medical University of Vienna in Austria. "Approximately 85 percent or more of precancerous lesions of the cervix were attributed to the nine HPV types covered in the vaccine; therefore, if nine-valent HPV vaccination programs are effectively implemented, the majority of these lesions could be prevented.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|